Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.

Cancer research - 18 Jan 2023

Malone Clare F, Kim Minjee, Alexe Gabriela, Engel Kathleen, Forman Alexandra B, Robichaud Amanda, Conway Amy Saur, Goodale Amy, Meyer Ashleigh, Khalid Delan, Thayakumar Allen, Hatcher John M, Gray Nathanael S, Piccioni Federica, Stegmaier Kimberly

Abstract excerpt

Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single-agent MEK inhibitors is common, however, and combination therapies are typically required to achieve significant clinical benefit in advanced cancers. Here we focused on identifying MEK inhibitor-based combination therapies in neuroblastoma with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Neuroblastoma

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36398965
DOI: 10.1158/0008-5472.CAN-21-4309
PMCID: PMC9938728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.PMID 36398965Read ↗

A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastomaSemantic proximity Read ↗

Genome-wide functional CRISPR screen reveals CDK7 as a targetable therapeutic vulnerability for head and neck cancerSemantic proximity Read ↗

Functional genomics identifies therapeutic targets for MYC-driven cancerSemantic proximity Read ↗

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsSemantic proximity Read ↗

Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models.Semantic proximity Read ↗

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancerSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair PathwaysSemantic proximity Read ↗

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.Semantic proximity Read ↗

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastomaSemantic proximity Read ↗

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Semantic proximity Read ↗

Oncogenic signaling of MEK5-ERK5.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.